Recently, Shenzhen RooterTech Biopharmaceutical Co., Ltd. (hereinafter referred to as "Raytoderma Biotechon") announced the completion of an angel round of financing of tens of millions of yuan. This round of financing was funded by Daotong Investment, Qinzhi Capital, National High-performance Medical Device Innovation Center, Jiankai Technology (688356. SH) co-investment. The funds will be used to advance the clinical trials of the company's core pipeline and accelerate the technology development and pipeline expansion of the iSus sustained-release platform.

Founded in 2021, Ray Visioner Biotech is committed to solving the pain points of frequent administration of eye drop dosage forms with ocular degradable long-acting sustained-release technology as the core. Its core platform technology, iSus, can achieve a single number of days to months of sustained drug delivery on the ocular surface and fundus, thereby significantly improving patients' treatment compliance and prognosis.

Ocular drug drops are a typical treatment for eye diseases, but the active drug ingredient has a short residence time on the ocular surface, low bioavailability, and slow onset of action. For patients with chronic eye diseases, it is difficult to strictly follow the doctor's instructions for a long time. After cataract and refractive surgery, anti-inflammatory and analgesic drugs must be instilled frequently for 3-4 weeks to complete perioperative care. A variety of subjective and objective factors may lead to poor medication compliance and less than expected treatment effects, which has been widely recognized by ophthalmologists, and there is an urgent need for a new treatment that can achieve long-term stable release of drugs.

Globally, only three extended-release treatment options for ocular degradable drugs developed by overseas companies have been approved, such as the anterior chamber implant drug developed by Allergan for the treatment of glaucoma and the vitreous implant for the treatment of fundus macular edema, and the lacrimal canal insertion drug developed by Ocular for anti-inflammatory and analgesic treatment after ocular surgery. The scarcity of approved products is mainly due to the fact that the research and development of products in this field is multidisciplinary, with a long cycle and a low success rate. The research and development of degradable sustained-release drugs involves multiple disciplines such as materials science, pharmacy, chemical engineering and medicine, and faces many technical problems, such as the biocompatibility and degradability of materials, the stability and release control of drugs, and the quality control of microunit chemical processes.

After 3 years, the team has broken through a number of core technical problems such as formulation process, degradation cycle control, and automated mass production, and successfully developed the iSus degradable long-term sustained-release technology platform, which can be widely used in the long-term sustained-release needs of human and pet ophthalmology in the future.

The first product is aimed at moderate to severe dry eye syndrome, which can play the physical effect of punctal plug and the drug effect of immunosuppression at the same time, and a single dose can last for several months, reducing the burden of multiple daily dosing for patients. The exquisite design ensures comfortable and stable insertion, improves compliance and treatment effect, and provides doctors with more innovative, efficient and inclusive treatment methods.

Commenting on this round of financing, Dr. Yanbo Ling, founder of Rayton, said: "We would like to express our sincere gratitude to all investors for their trust and support, and we will accelerate the clinical advancement of our first product, provide ophthalmologists with more efficient treatment methods, and solve the urgent needs of 120 million patients with moderate to severe dry eye in China." Based on the iSus platform, we will explore more possibilities in the field of long-acting sustained-release ophthalmic drug delivery, accelerate the development and commercialization of innovative products, and strive to become a leader in the field of ocular drug delivery." ”

Daotong Investment said: "Ophthalmology is one of the key tracks of Daotong Investment in the field of medical and health care. Through the regulation of polymer material formulations, the technology platform of Raytoderm Biotech is expected to achieve sustained release of different drugs for different durations, thereby providing a comprehensive solution for long-term drug delivery of many eye diseases. The first product treats dry eye syndrome in an innovative way with a combination of drugs and devices, and the market has room for imagination. We are excited to participate in this investment and look forward to working with RETonel to bring innovative products to market as soon as possible, bringing patients a more comfortable treatment experience and better efficacy." ”